These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25732554)

  • 21. Developing an anticancer copper(II) pro-drug based on the nature of cancer cell and human serum albumin carrier IIA subdomain: mouse model of breast cancer.
    Gou Y; Zhang Y; Qi J; Chen S; Zhou Z; Wu X; Liang H; Yang F
    Oncotarget; 2016 Oct; 7(41):67004-67019. PubMed ID: 27564255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tuning of poly-S-nitrosated human serum albumin as superior antitumor nanomedicine.
    Ishima Y; Fang J; Kragh-Hansen U; Yin H; Liao L; Katayama N; Watanabe H; Kai T; Suenaga A; Maeda H; Otagiri M; Maruyama T
    J Pharm Sci; 2014 Jul; 103(7):2184-2188. PubMed ID: 24846171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In silico prediction of human serum albumin binding for drug leads.
    Vallianatou T; Lambrinidis G; Tsantili-Kakoulidou A
    Expert Opin Drug Discov; 2013 May; 8(5):583-95. PubMed ID: 23461733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unraveling the binding mechanism of asiatic acid with human serum albumin and its biological implications.
    Gokara M; Malavath T; Kalangi SK; Reddana P; Subramanyam R
    J Biomol Struct Dyn; 2014; 32(8):1290-302. PubMed ID: 23844909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A New Carbon Nanotube-Based Breast Cancer Drug Delivery System: Preparation and In Vitro Analysis Using Paclitaxel.
    Shao W; Paul A; Rodes L; Prakash S
    Cell Biochem Biophys; 2015 Apr; 71(3):1405-14. PubMed ID: 27101155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interaction of anticancer drug clofarabine with human serum albumin and human α-1 acid glycoprotein. Spectroscopic and molecular docking approach.
    Ajmal MR; Nusrat S; Alam P; Zaidi N; Khan MV; Zaman M; Shahein YE; Mahmoud MH; Badr G; Khan RH
    J Pharm Biomed Anal; 2017 Feb; 135():106-115. PubMed ID: 28012306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Binding of an anticancer drug, axitinib to human serum albumin: Fluorescence quenching and molecular docking study.
    Tayyab S; Izzudin MM; Kabir MZ; Feroz SR; Tee WV; Mohamad SB; Alias Z
    J Photochem Photobiol B; 2016 Sep; 162():386-394. PubMed ID: 27424099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives.
    Lazarević T; Rilak A; Bugarčić ŽD
    Eur J Med Chem; 2017 Dec; 142():8-31. PubMed ID: 28442170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapeutic Drugs and Plasma Proteins: Exploring New Dimensions.
    Zia MK; Siddiqui T; Ali SS; Rehman AA; Ahsan H; Khan FH
    Curr Protein Pept Sci; 2018; 19(10):937-947. PubMed ID: 28969563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-targeted intracellular delivery of anticancer drugs through the mannose-6-phosphate/insulin-like growth factor II receptor.
    Prakash J; Beljaars L; Harapanahalli AK; Zeinstra-Smith M; de Jager-Krikken A; Hessing M; Steen H; Poelstra K
    Int J Cancer; 2010 Apr; 126(8):1966-1981. PubMed ID: 19795464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Designing anticancer multitarget metal thiosemicarbazone prodrug based on the nature of binding sites of human serum albumin carrier.
    Yang F; Liang H
    Future Med Chem; 2018 Aug; 10(16):1881-1883. PubMed ID: 29925269
    [No Abstract]   [Full Text] [Related]  

  • 32. Design of an Anticancer Copper(II) Prodrug Based on the Lys199 Residue of the Active Targeting Human Serum Albumin Nanoparticle Carrier.
    Gou Y; Zhang Y; Zhang Z; Wang J; Zhou Z; Liang H; Yang F
    Mol Pharm; 2017 Jun; 14(6):1861-1873. PubMed ID: 28471669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Binding of anticancer drugs to human serum albumin studied by reversed-phase chromatography.
    Forgács E; Cserháti T
    J Chromatogr A; 1995 Apr; 696(2):265-72. PubMed ID: 7749487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Developing Anticancer Copper(II) Pro-drugs Based on the Nature of Cancer Cells and the Human Serum Albumin Carrier IIA Subdomain.
    Gou Y; Qi J; Ajayi JP; Zhang Y; Zhou Z; Wu X; Yang F; Liang H
    Mol Pharm; 2015 Oct; 12(10):3597-609. PubMed ID: 26354410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Studies on drug-human serum albumin binding: the current state of the matter.
    Zhivkova ZD
    Curr Pharm Des; 2015; 21(14):1817-30. PubMed ID: 25732557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human plasma lipocalins and serum albumin: Plasma alternative carriers?
    di Masi A; Trezza V; Leboffe L; Ascenzi P
    J Control Release; 2016 Apr; 228():191-205. PubMed ID: 26951925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring the effect of the ligand design on the interactions between [Ru(η(5)-C5H5)(PPh3)(N,O)][CF3SO3] complexes and human serum albumin.
    Morais TS; Santos FC; Corte-Real L; Garcia MH
    J Inorg Biochem; 2013 Dec; 129():94-101. PubMed ID: 24096130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multidrug Delivery Systems Based on Human Serum Albumin for Combination Therapy with Three Anticancer Agents.
    Qi J; Zhang Y; Gou Y; Lee P; Wang J; Chen S; Zhou Z; Wu X; Yang F; Liang H
    Mol Pharm; 2016 Sep; 13(9):3098-105. PubMed ID: 27453125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The advancement of human serum albumin-based molecular probes for molecular imaging.
    Cao W; Lu X; Cheng Z
    Curr Pharm Des; 2015; 21(14):1908-15. PubMed ID: 25732549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?
    Thota S; Rodrigues DA; Crans DC; Barreiro EJ
    J Med Chem; 2018 Jul; 61(14):5805-5821. PubMed ID: 29446940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.